A Randomized Phase II Trial of Atezolizumab with or without Tiragolumab Before and After Definitive Chemoradiation for Unresectable Stage III NSCLC (AFT-57)
- Citation:
- J Clin Oncol vol 24 (16_suppl) TPS8123
- Meeting Instance:
- ASCO 2024
- Year:
- 2024
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- AFT
- Endpoint:
- No-Endpoint
- Analysis:
- Trial-Description-Only
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Genentech
- Grants:
- AFT
- Corr. Author:
- Authors:
- Helen J. Ross David Kozono Michael Mix James Urbanic Terence Williams Taylor O'Donnell Ilze Bara Katja Schulze Xiaofei Wang Garth Nelson Thomas E. Stinchcombe
- Networks:
- CA043, CA249, IL043, LAPS-MA036, LAPS-MN026, LAPS-NC010, NY141
- Study
- AFT-57
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: